The Federal Trade Commission is continuing its fight against alleged anti-competitive behavior in the U.S. pharmaceutical industry by pushing for federal legislation that would bar makers of brand-name prescription drugs from paying generic drug manufacturers to delay a generic drug release.
The agency said the sharp rise of such anti-competitive settlements between the two types of drug makers deprives consumers of affordable prescription drugs.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]